AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
AIM ImmunoTech (NYSE American: AIM) announced the election results from its 2024 Annual Meeting of Stockholders. Three incumbent directors - Nancy K. Bryan, Thomas K. Equels, and Dr. William M. Mitchell - were re-elected to the Board of Directors, along with new member Ted D. Kellner. The meeting achieved the required 40% quorum of outstanding shares entitled to vote.
Dr. Mitchell, Board Chairman, expressed gratitude to shareholders for their support and trust in the company's clinical development strategy, particularly regarding their lead drug candidate, Ampligen. The company aims to focus on supporting high-value cancer clinical development programs in areas with critical unmet needs.
AIM ImmunoTech (NYSE American: AIM) ha annunciato i risultati delle elezioni della sua Assemblea Annuale degli Azionisti del 2024. Tre membri uscenti del consiglio - Nancy K. Bryan, Thomas K. Equels e il Dr. William M. Mitchell - sono stati rielevati nel Consiglio di Amministrazione, insieme al nuovo membro Ted D. Kellner. L'incontro ha raggiunto il quorum richiesto del 40% delle azioni in circolazione aventi diritto di voto.
Il Dr. Mitchell, Presidente del Consiglio, ha espresso gratitudine agli azionisti per il loro supporto e fiducia nella strategia di sviluppo clinico dell'azienda, in particolare riguardo al loro principale candidato farmaceutico, Ampligen. L'azienda intende concentrarsi sul supporto a programmi di sviluppo clinico per il cancro di alto valore in aree con bisogni insoddisfatti critici.
AIM ImmunoTech (NYSE American: AIM) anunció los resultados de las elecciones en su Asamblea Anual de Accionistas de 2024. Tres directores en funciones - Nancy K. Bryan, Thomas K. Equels y el Dr. William M. Mitchell - fueron reelegidos para la Junta Directiva, junto con el nuevo miembro Ted D. Kellner. La reunión alcanzó el quórum requerido del 40% de las acciones en circulación con derecho a voto.
El Dr. Mitchell, Presidente de la Junta, expresó su agradecimiento a los accionistas por su apoyo y confianza en la estrategia de desarrollo clínico de la empresa, especialmente en relación con su principal candidato a fármaco, Ampligen. La empresa pretende centrarse en apoyar programas de desarrollo clínico en oncología de alto valor en áreas con necesidades insatisfechas críticas.
AIM ImmunoTech (NYSE American: AIM)는 2024년 주주 총회에서의 선거 결과를 발표했습니다. 세 명의 현직 이사인 Nancy K. Bryan, Thomas K. Equels과 Dr. William M. Mitchell이 이사회에 재선 되었고, 새로운 멤버인 Ted D. Kellner가 합류했습니다. 이번 회의는 투표권이 있는 발행주식의 40%의 쿼럼을 달성하였습니다.
이사회 의장인 Mitchell 박사는 주주들에게 회사의 임상 개발 전략에 대한 지지와 신뢰에 감사의 뜻을 전하며, 주요 약물 후보물질인 Ampligen에 대해 강조했습니다. 회사는 치명적인 unmet needs가 있는 분야에서 높은 가치를 지닌 암 임상 개발 프로그램을 지원하는 데 집중할 계획입니다.
AIM ImmunoTech (NYSE American: AIM) a annoncé les résultats des élections de son Assemblée Générale Annuelle des Actionnaires de 2024. Trois administrateurs en poste - Nancy K. Bryan, Thomas K. Equels et le Dr. William M. Mitchell - ont été réélus au Conseil d'Administration, avec le nouveau membre Ted D. Kellner. La réunion a atteint le quorum requis de 40 % des actions en circulation ayant droit de vote.
Le Dr. Mitchell, Président du Conseil, a exprimé sa gratitude aux actionnaires pour leur soutien et leur confiance dans la stratégie de développement clinique de l'entreprise, en particulier concernant leur principal candidat médicament, Ampligen. L'entreprise vise à se concentrer sur le soutien de programmes de développement clinique de grande valeur en oncologie dans des domaines où des besoins critiques restent insatisfaits.
AIM ImmunoTech (NYSE American: AIM) gab die Wahlergebnisse seiner Jahreshauptversammlung 2024 bekannt. Drei amtierende Direktoren - Nancy K. Bryan, Thomas K. Equels und Dr. William M. Mitchell - wurden gemeinsam mit dem neuen Mitglied Ted D. Kellner in den Vorstand wiedergewählt. Die Sitzung erreichte das erforderliche Quorum von 40% der stimmberechtigten ausgegebenen Aktien.
Dr. Mitchell, der Vorsitzende des Vorstands, sprach den Aktionären seinen Dank für ihre Unterstützung und ihr Vertrauen in die klinische Entwicklungsstrategie des Unternehmens aus, insbesondere in Bezug auf den Hauptkandidaten Ampligen. Das Unternehmen beabsichtigt, sich auf die Unterstützung von hochqualitativen klinischen Entwicklungsprogrammen im Bereich Krebs zu konzentrieren, insbesondere in Bereichen mit kritischem ungedecktem Bedarf.
- Successfully completed board election with required quorum
- Maintained board continuity with three incumbent directors
- Added new board member expanding leadership expertise
- None.
Dr. William M. Mitchell, Chairman of the Board, stated:
“We would like to sincerely thank our shareholders for their support and engagement throughout this process and are grateful for their trust in our clinical development strategy. The AIM Board is fully committed to the Company’s success and the potential of our lead drug candidate, Ampligen. We are glad to put this proxy contest behind us and focus on supporting our high value cancer clinical development programs in areas with critical unmet needs.
“We would like to thank Stewart Appelrouth for his dedicated service on the Board. Additionally, we look forward to working constructively with Mr. Kellner in the boardroom as we pursue our significant opportunities with Ampligen and deliver significant long-term value for all shareholders.”
The Company notes the requisite quorum of
The results announced today are considered preliminary until final results are tabulated and certified by the independent Inspector of Elections. Final results will be reported on a Form 8-K that will be filed with the Securities and Exchange Commission.
***
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217411265/en/
Investor Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
AIM@jtcir.com
Media Contact:
Longacre Square Partners
Joe Germani / Miller Winston
AIM@longacresquare.com
Source: AIM ImmunoTech Inc.
FAQ
Who were the directors elected to AIM ImmunoTech's board at the 2024 Annual Meeting?
What was the required quorum for AIM's 2024 Annual Meeting?
What is AIM ImmunoTech's main drug candidate mentioned in the 2024 board meeting?
What is AIM ImmunoTech's current clinical development focus?
